Agar in the management of hyperbilirubinaemia in the premature baby

C. ROMAGNOLI, G. POLIDORI, M. FOSCHINI, L. CATALDI, P. DE TURRIS, G. TORTOROLO, and R. MASTRANGELO

From Clinica Pediatrica, Università Cattolica del S. Cuore, Roma, Italy

Romagnoli, C., Polidori, G., Foschini, M., Cataldi, L., De Turris, P., Tortorolo, G., and Mastrangelo, R. (1975). *Archives of Disease in Childhood, 50*, 202. Agar in the management of hyperbilirubinaemia in the premature baby. Eighty low birthweight infants (1500 to 2500 g) were randomly assigned to a group given oral agar and a control group. The study was first performed in 24 agar-fed babies and 24 control babies. The treated infants received a daily total amount of 600 mg/kg of agar beginning at 12 hours of age, for 7 days. In the later stage of the trial, 16 agar-fed babies and 16 control babies were investigated. The total daily amount of agar was raised to 700 mg/kg, beginning at 6 hours of age for 7 days.

No complications were observed with the administration of agar. Serum bilirubin levels were not significantly lower in the agar-fed infants. We conclude that agar supplemented feeding is not indicated in the management of hyperbilirubinaemia in low birthweight newborn infants.

Phototheraphy is highly effective in both prevention and treatment of neonatal hyperbilirubinaemia. Serious untoward reactions have not been reported, although the possibility of such toxicity cannot be excluded at the present time (Behrman *et al*., 1974). An alternative approach has been suggested by recent work (Poland and Odell, 1971), showing that lower levels of serum bilirubin occur in agar-fed term infants with 'physiological' hyperbilirubinaemia. The purpose of this communication is to report our experience with agar in the control of neonatal hyperbilirubinaemia in premature infants.

**Methods**

80 low birthweight infants (1500 to 2500 g) were randomly assigned to a therapy group and to a control group. The study was performed first in 24 agar-fed babies and in 24 control babies. The treated infants received a daily total amount of 600 mg/kg agar* beginning at 12 hours of age and continuing for 7 days. Later in the trial, 16 agar-fed babies and 16 control babies were investigated and the total daily amount of agar was raised to 700 mg/kg, beginning at 6 hours of age and continuing for 7 days.

Infants in each group were similar with respect to mean birthweight, gestational age, and sex (Table).

![TABLE](http://adc.bmj.com/)

<table>
<thead>
<tr>
<th>Group</th>
<th>No. of infants</th>
<th>Sex ratio (M:F)</th>
<th>Birthweight (g) (mean ± SE)</th>
<th>Gestational age (w) (mean ± SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First study group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agar-fed</td>
<td>24</td>
<td>11:13</td>
<td>2240 ± 40 ± 1</td>
<td>35 ± 0.9 ± 60</td>
</tr>
<tr>
<td>Controls</td>
<td>24</td>
<td>11:13</td>
<td>2118 ± 52 ± 0</td>
<td>35 ± 31 ± 50</td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td><strong>Second study group</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agar-fed</td>
<td>16</td>
<td>6:10</td>
<td>2265 ± 47 ± 6</td>
<td>35 ± 78 ± 80</td>
</tr>
<tr>
<td>Controls</td>
<td>16</td>
<td>6:10</td>
<td>2180 ± 60 ± 0</td>
<td>35 ± 13 ± 60</td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td>&gt;0.05</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

Infants with haemolytic anaemia, respiratory distress syndrome, sepsis, or malformations were excluded from the study. Blood groups, Rh factor, Coombe's test, haemoglobin, RBC and WBC counts, haematocrit, reticulocyte count, blood glucose, serum, calcium, G6PD (Beutler test) and acid-base status were determined for each baby in the first day of life. Daily measurements of total serum bilirubin concentrations were performed between 8 and 9 a.m. for 8 days by the same technician according to the method of Malloy and Evelyn (1937). Conjunctival bilirubin measurements were performed on the 3rd day of age. Daily weights and stools were recorded for each infants. All


Received 29 July 1974.
Agar in the management of hyperbilirubinaemia in the premature baby

Results

No complications were observed with the administration of agar. There was no significant difference in haematocrit and weight values between treated and control infants. No diarrhoea or bulky stools were noted in the agar-fed infants. Conjugated bilirubin values were all within normal limits.

In the first trial (Fig. 1), the agar-fed infants had a rise of mean serum bilirubin concentration from 3.6 mg/100 ml (SE ± 0.3) on the first day to 11.4 mg/100 ml (SE ± 0.8) on the 5th day of life, whereas the serum bilirubin concentration in the control infants increased from the initial value of 4.1 mg/100 ml (SE ± 0.4) to a maximum of 11.4 mg/100 ml (SE ± 0.8) on the 4th day of life.

In the second trial (Fig. 2) the mean serum bilirubin concentration of the agar-treated babies rose from 3.2 mg/100 ml (SE ± 0.3) on the first day to 13.8 mg/100 ml (SE ± 1.0) on the 5th day of life. In the control group the serum bilirubin rose from 3.7 mg/100 ml (SE ± 0.3) on the first day to 12.5 mg/100 ml (SE ± 1.4) on the 4th day.

No statistically significant difference was noted in the number of exchange transfusions required by the treated infants versus controls in each set of premature infants investigated: 2 versus 4 exchange transfusions in the first trial, 2 versus 5 exchange transfusions in the second trial.

Discussion

The role of enterohepatic circulation of bilirubin in 'physiological' hyperbilirubinaemia has not been well established (Brodersen and Hermann, 1963; Gilbertsen, Bossenmaier and Cardinal 1962; Lester and Schmid, 1963; Ulstrom and Eisenklam, 1964), although Poland and Odell (1971) have shown that reabsorption of bilirubin from the intestine may be a major contributory factor. They reported no further rise in neonatal serum bilirubin concentrations in term infants when a formula supplemented with agar was given. At the same time an increased excretion of bilirubin in the faeces was shown. Our results failed to detect any significant serum bilirubin reduction in agar-fed low birthweight infants.

The USP agar used in these 2 studies was one of the most effective lots, and the failure of agar to reduce the degree of hyperbilirubinaemia, therefore, cannot be attributed to the reduced capacity of the specific preparation to 'sequester' bilirubin in the intestinal tract. It is possible that a dosage factor may be critical in low birthweight infants as compared to term infants. However, the higher dosage of agar attempted in the second trial of our study did not produce any significant reduction of serum bilirubin. It has been postulated that agar may also prevent reabsorption of the bilirubin within the gut at the time of birth, which can be partially responsible for 'physiological' hyperbilirubinaemia. On the basis of this assumption
204 Romagnoli, Polidori, Foschini, Cataldi, De Turris, Tortorolo, and Mastrangelo

we began agar administration earlier—6 hours after birth—in the second set of low birthweight infants investigated. There was still no significant effect.

Perhaps the enterohepatic circulation of bilirubin plays no significant part in the mechanism of hyperbilirubinaemia in premature infants. In any case, we agree with Maurer et al., (1973) who had a similar experience although in a small number of cases, that agar-supplemented feeding is not indicated in the management of hyperbilirubinaemia in low birthweight newborn infants.

The authors acknowledge the assistance of the nurses of the Premature Infants Centre (head nurse, Miss G. Farnedi), the parents who made this study possible, and Dr. R. L. Poland (Detroit, Michigan) who supplied the agar.

REFERENCE;


Correspondence to Dr. C. Romagnoli, Clinica Pediatrica, Università Cattolica del S. Cuore, Largo A. Gemelli 8, 00168 Roma, Italy.